Advertisement
UK markets close in 1 hour 19 minutes

  • FTSE 100

    8,039.08
    -1.30 (-0.02%)
     

  • FTSE 250

    19,549.01
    -170.36 (-0.86%)
     

  • AIM

    752.22
    -2.47 (-0.33%)
     

  • GBP/EUR

    1.1650
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2471
    +0.0008 (+0.07%)
     

  • Bitcoin GBP

    51,015.86
    -2,043.16 (-3.85%)
     

  • CMC Crypto 200

    1,369.58
    -12.99 (-0.94%)
     

  • S&P 500

    5,003.35
    -68.28 (-1.35%)
     

  • DOW

    37,797.50
    -663.42 (-1.72%)
     

  • CRUDE OIL

    82.48
    -0.33 (-0.40%)
     

  • GOLD FUTURES

    2,332.10
    -6.30 (-0.27%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,807.69
    -281.01 (-1.55%)
     

  • CAC 40

    7,959.36
    -132.50 (-1.64%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Shire to buy Baxalta for $32 bln, forging rare diseases leader

Reuters - UK Focus

LONDON, Jan 11 (Reuters) - Drugmaker Shire Plc clinched its six-month pursuit of Baxalta International Inc on Monday by agreeing a $32 billion cash and stock offer that will make it one of the world's leading rare disease specialists.

The London-listed group, which first approached the U.S (Other OTC: UBGXF - news) . firm with an all-stock offer in July, won over the maker of treatments for rare blood conditions, cancers and immune system disorders after adding a cash sweetener.

Shareholders will receive $18.00 in cash and 0.1482 Shire (Hamburg: 3979575.HM - news) American depositary shares per Baxalta (Berlin: 9BX.BE - news) share, implying a total value of $45.57 per share based on Jan. 8 prices. (Reporting by Ben Hirschler; editing by Jason Neely)